FeesSafety
Pluang+

Shelton Equity Premium Income ETF offers 8% yield with capital preservation but has higher volatility and risks.

Market News
29 Oct 2026, 14:15 WIB
Seeking Alpha
View Source
Neutral
Shelton Equity Premium Income ETF offers 8% yield with capital preservation but has higher volatility and risks.

The Shelton Equity Premium Income ETF (SEPI) delivers an 8% yield using a covered call strategy on a focused U.S. stock portfolio. Since its inception, SEPI has outperformed its buy-write benchmark and most competitors, though it shows higher volatility and a lower yield compared to some peers. The ETF is rated as a 'Hold' due to its short track record, low assets under management, concentrated portfolio, and limited transparency. Despite these risks, SEPI's strong start and ability to preserve capital make it an interesting option for investors seeking derivative income strategies.

The Shelton Equity Premium Income ETF (SEPI) is noted for its 8% yield using a covered call strategy, providing context for readers interested in derivative income strategies. For readers following US stocks on Pluang, here is the market snapshot as of Oct 29, 2026 17:41 WIB: out of 150 priced US stocks, 86 rose and 62 fell. Notable movers include INTC at USD 92.00 with a 1-day change of -3.70%, SNOW at USD 329.08 down 3.19%, and ACN at USD 236.00 down 3.04%, with varied typical hold times and Pluang order activity ratios.

More News

NCH performs US first tricuspid valve repair with PASCAL Precision system after FDA approval

NCH performs US first tricuspid valve repair with PASCAL Precision system after FDA approval

Naples Comprehensive Health (NCH) has completed the first tricuspid valve repair in the US using the PASCAL Precision system following FDA approval. This minimally invasive catheter-based procedure offers a new treatment option for patients with seve...

Market News
Bullish
1 hour ago
Immunocore to present Phase 1 data on brenetafusp and KIMMTRAK combo for metastatic uveal melanoma at SITC 2026

Immunocore to present Phase 1 data on brenetafusp and KIMMTRAK combo for metastatic uveal melanoma at SITC 2026

Immunocore Holdings will present Phase 1/2 clinical trial data for brenetafusp alone and combined with KIMMTRAK in treating metastatic uveal melanoma at the 2026 Society for Immunotherapy of Cancer meeting. This trial evaluates safety and efficacy in...

Company Fundamentals
Bullish
1 hour ago
Collegium Pharmaceutical and Boston Legacy FC expand partnership to support neurodivergent youth in Massachusetts sports.

Collegium Pharmaceutical and Boston Legacy FC expand partnership to support neurodivergent youth in Massachusetts sports.

Collegium Pharmaceutical and Boston Legacy FC have extended their partnership to include youth coach training, an annual Sports for All Summit, and sensory inclusion programs aimed at supporting neurodivergent children, especially those with ADHD, in...

Others
Bullish
2 hours ago
Gilat Satellite Networks to attend Deutsche Bank Global Space and Defense Tech Summit in NYC

Gilat Satellite Networks to attend Deutsche Bank Global Space and Defense Tech Summit in NYC

Gilat Satellite Networks announced that its CEO Adi Sfadia and CFO Gil Benyamini will attend the Deutsche Bank Global Space and Defense Tech Summit on November 18, 2026, in New York City. The event will feature one-on-one and group meetings, providin...

Market News
Neutral
2 hours ago
Boralex buys Wind2 to boost UK wind energy projects by 350 MW, expanding its renewable footprint.

Boralex buys Wind2 to boost UK wind energy projects by 350 MW, expanding its renewable footprint.

Boralex Inc. has acquired Wind2, a UK-based renewable energy developer with about 350 MW of advanced wind projects across Scotland, England, and Wales. This acquisition strengthens Boralex's presence and capabilities in the UK, aligning with its stra...

Company Fundamentals
Bullish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App